Daiichi Sankyo Company, Limited · TSE:4568
Daiichi Sankyo — Q2 FY2014 Earnings Presentation
25 slides from Daiichi Sankyo's earnings presentation, Nov 4, 2014
Slide 1: Top Management Presentation
Top Management Presentation Financial Results for 2Q FY2014 (April 1 – September 30, 2014) Joji Nakayama President and CEO November 4, 2014 0
Slide 2: Today's Topics
Today’s Topics FY2014 2Q Results FY2014 revised consolidated forecast Business Update Optimization of Business Operation Structure in Japan R&D Update 1
Slide 3: FY2014 2Q Results
O Daiichi-Sankyo FY 2014 2Q Results
Slide 4: Overview of FY2014 2Q Results
Overview of FY2014 2Q Results Consolidated Statement of Profit or Loss Daiichi Sankyo Group JPY Bn JPY Bn FY2013 FY2014 FY2013 FY2014 Revised YoY YoY 2Q Result 2Q Result 2Q Result 2Q Result Plan* +0.1% 920.0 Revenue 516.8 525.4 +8.6 Revenue 429.1 429.6 +0.5 900.0 Cost of sales 174.1 176.1 +2.1 Cost
Slide 5: FY2014 2Q Revenue
FY2014 2Q Revenue (JPY Bn) Positive Factors Negative Factors Decline in Japan and Daiichi Sankyo Inc. offsetted by growth of Luitopold and ASCA Consolidated Statement of Profit or Loss Daiichi Sankyo Group 400.0 410.0 420.0 430.0 500.0 510.0 520.0 530.0 FY2013 Q2 Results 429.1 FY2013 Q2 Results 516.
Slide 6: FY2014 2Q Operating Profit
FY2014 2Q Operating Profit Positive Factors Negative Factors (JPY Bn) Operating profit increase reflected decreases in SG&A expenses and R&D expenses Consolidated Statement of Profit or Loss Daiichi Sankyo Group 40.0 50.0 60.0 70.0 20.0 30.0 40.0 50.0 60.0 FY2013 Q2 Results 52.7 FY2013 Q2 Results 50
Slide 7: FY2014 2Q Profit attributable to owners of the Company
FY2013 1Q Profit attributable to Positive Negative owners of the Company (JPY Bn) Factors Factors Profit (attributable to owners of the Company) increase owing to the operating profit increase and an improvement in financial income/expenses Consolidated Statement of Profit or Loss Daiichi Sankyo Gro
Slide 8: FY2014 revised consolidated forecast
FY2014 revised consolidated forecast
Slide 9: FY2014 revised consolidated forecast
FY2014 revised consolidated forecast JPY Bn FY 2013 FY 2013 Forecast Revised Forecast change (July) (October) Revenue 920.0 900.0 -20.0 Cost of sales 285.0 280.0 -5.0 R&D expenses 182.0 182.0 0 SG&A expenses 333.0 338.0 +5.0 Operating Profit 120.0 100.0 -20.0 Profit before tax 120.0 100.0 -20.0 Prof
Slide 10: Summary of the revised FY2014 forecast
Summary of the revised FY2014 forecast Sales growth of mainstay products in Japan at a rate below initial forecasts, Sales decline of long listed products at a greater rate than initially Revenue forecasted as a result of expansion in prescriptions of generic products, Intensified price competition
Slide 11: Business Update
O Daiichi-Sankyo Business Update
Slide 12: Major Products in Japan
Major Products in Japan JPY Bn Revised 2013Q2 2014Q2 Result Result YoY Forecast Change To Plan (Oct.) Olmetec anti-hypertension 37.6 37.8 +0.3 79.0 48% anti-ulcer Nexium (Proton Pump Inhibitor) 24.0 32.1 +8.1 67.0 48% analgesic and anti- Loxonin inflammatory 30.7 25.4 -5.3 48.0 -4.0 53% treatment fo
Slide 13: Initiatives for Mainstay Products in Japan
Initiatives for Mainstay Products in Japan Olmetec Use home blood pressure data Emphasize appeal of excellent antihypertensive effect and consistency Keep No. 1 ARB share ネキシウム Nexium In 3rd year after launch, gain overwhelming market share through strong partnership with AstraZeneca Promo
Slide 14: Initiatives for Mainstay Products in Japan
Initiatives for Mainstay Products in Japan Memary Emphasize appeal of advancement suppression effects from combination with Donepezil Steadily spread orally disintegrating (OD) tablet Secure new prescriptions and provide continuous education on disease by clarifying symptoms Memary® is effecti
Slide 15: Major Business Units
Major Business Units JPY Bn Revised FY2013Q2 FY2014Q2 Result Result YoY Forecast Change To plan (Oct.) Japan Company + Vaccine business 227.6 222.6 -4.9 480.0 -28.0 46% Daiichi Sankyo Healthcare 23.0 22.7 - 0. 3 48.0 47% Daiichi Sankyo Inc. 86.5 78.1 -8.4 161.0 -3.0 49% Olmesartan 56.8 47.2 -9.6 98.
Slide 16: Merger of Ranbaxy with Sun Pharma
Merger of Ranbaxy with Sun Pharma Agreements for a merger of Ranbaxy with Sun Pharma on April 6, 2014 Approved at the respective general shareholders’ meetings of Ranbaxy and Sun Pharma by September 30, 2014 • The final examinations by the relevant authorities are currently in progress • Daiichi
Slide 17: Optimization of Business Operation Structure in Japan
Optimization of Business Operation Structure in Japan
Slide 18: Optimization of Business Operation Structure in Japan: Background and Aims
Optimization of Business Operation Structure in Japan Background • Improve SG&A ratio that is higher than industry standard • Handle Olmesartan patent period expiration* Optimization of Business Operation Structure in Japan Aims • Strengthen business foundation to enable investment for sustainab
Slide 19: Optimization of Business Operation Structure in Japan
Optimization of Business Operation Structure in Japan Reform business operation in each unit • Self-sustaining business operation in each Japan business • Greater efficiency through reduction of indirect operations and concentration of operations • Expediting of decision making through simplified
Slide 20: R&D Update
Daiichi-Sankyo R&D Update
Slide 21: Progress in R&D pipeline
Progress in R&D pipeline Major change from 1Q FY2014 announcement Generic Name Target indication region Ph-1 Ph-2 Ph-3 Filed Approved Dev. Code 2014年度 第1四半期決算発表からの主な変更点 Prevention of stroke and systemic embolism JP in patients with NVAF Edoxaban Treatment of DVT and prevention of recurrent JP VTE Mi
Slide 22: CL-108: Hydrocodone combination
CL-108: Hydrocodone combination In-license product from Charleston Laboratories Inc.* Exclusive license for commercialization in US Hydrocodone**・acetaminophen・promethazine (immediate release) combination • To be used for managed care for patients with from mid to severe acute pain • Decrease
Slide 23: AC220 / Quizartinib
AC220 / Quizartinib Acquired Ambit Bioscience by TOB MOA:FLT3 (Fms-Like Tyrosine Kinase 3)-ITD*inhibitor (*ITD:Internal Tandem Duplication) Target indication: FLT3-ITD mutation positive acute myeloid leukemia (AML) • FLT3-ITD mutation is observed in 30% of patients with AML, resulted in poor c
Slide 24: Major R&D Pipeline
Major R&D Pipeline As of October 2014 Therapeutic area Phase 1 Phase 2 Phase 3 Application DS-1040 CS-3150 (JP) Prasugrel (JP) Edoxaban (US/EU/Others) (Acute ischemic stroke / TAFIa (Hypertensive / DM nephropathy / (CS-747 / ischemic stroke / anti- (DU-176b / AF / oral factor Xa inhibitor) C
Slide 25: Contact: Corporate Communications Department
Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1126 Financial forecasts, future projections and R&D information that Daiichi Sankyo discloses may include information that might be classified as “Forward Looking Statement”. These f
Daiichi Sankyo Company — Q2 FY2014 Earnings Presentation on 6ix